KOD
Live chart
What they do
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases.
For information only · Important disclosures
Grades vs sector
No sector grades for KOD yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Held by 1 of 5 live models: New Highs Growth.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | -0.96 | -1.05 | -9.8% |
| 2026-05-07 | -1.01 | -0.94 | +7.1% |
| 2026-03-31 | -1.05 | -1.04 | +1.2% |
| 2025-11-13 | -1.04 | -1.16 | -11.5% |
| 2025-08-13 | -1.05 | -1.03 | +1.6% |
| 2025-05-14 | -0.87 | -1.09 | -24.7% |
| 2025-03-27 | -0.86 | -0.84 | +2.8% |
| 2024-11-14 | -0.90 | -0.84 | +6.6% |
Insider trades
$121.6K
$7.2K
$1.7M
$102.1K
$874.5K
$52.1K
$3.9M
$233.3K
$3.7M
$223.3K
$4.7M
$281.0K
Stats refreshed 2026-10-21 18:16:18 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026